8-K: Adagio Medical Reports Positive Pivotal Trial Results for vCLAS System

Adagio Medical announced positive six-month results from its FULCRUM-VT pivotal IDE trial for the vCLAS Ventricular Ablation System, meeting safety and effectiveness endpoints.

Summary

• Adagio Medical Holdings, Inc. reported positive six-month results from its FULCRUM-VT Investigational Device Exemption (IDE) clinical trial for the vCLAS Ventricular Ablation System.
• The trial results, presented at the Heart Rhythm Society 2026 conference, will support the company's application for FDA Premarket Approval.
• Key findings include 98% non-inducibility of targeted ventricular tachycardias (VT) at the end of the procedure, 84% freedom from ICD shock at 6 months, and 59% freedom from VT recurrence at 6 months.
• The system demonstrated equivalent effectiveness in both ischemic (ICM) and non-ischemic cardiomyopathy (NICM) patients, a first for ablation technology from an endocardial approach.
• The trial enrolled 209 patients across 20 centers in the U.S. and Canada, evaluating the vCLAS Cryoablation System.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, with strong clinical trial results that meet key endpoints and position the company for FDA approval and potential market leadership in a critical area of cardiac treatment.

Positives

• Achieved 84% freedom from implantable cardioverter defibrillator (ICD) shock at 6 months.
• Reported 59% freedom from any VT recurrence at 6 months.
• Demonstrated 98% non-inducibility of targeted ventricular tachycardias (VT) at the end of the procedure.
• Showed equivalent results for both ischemic (ICM) and non-ischemic cardiomyopathy (NICM) patients.
• Achieved over 80% reduction in patients experiencing ICD shock post-ablation compared to pre-ablation.
• 72% of patients discontinued or reduced their amiodarone dose at 6 months.
• Low 1.9% rate of 30-day VT-related hospital readmission.
• The vCLAS system showed a promising safety profile with a 2.4% rate of protocol-defined Major Adverse Events.

Negatives

• A 2.4% rate of major adverse events was reported, including two (1.0%) peri-procedural deaths adjudicated as possibly related to the investigational device.
• The study is still investigational in the United States, with commercial availability limited to Europe and select other geographies.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely.
• The company's business risks are detailed in its SEC filings, including its Annual Report on Form 10-K for the full-year ended December 31, 2025.

Future Outlook

The results of the FULCRUM-VT study will be used to support an application for FDA Premarket Approval (PMA) for the vCLAS Cryoablation System. The company believes its ULTA technology has the potential to become a foundational ablation technology for treating the ventricle and address a significant unmet need for treating complex arrhythmias.

Management Comments

• "FULCRUM-VT represents a seminal step forward in advancing ventricular tachycardia management by delivering positive, clinically meaningful results from the first large-scale, rigorously executed pivotal trial in patients with both ischemic and non-ischemic structural heart disease."
• "Importantly, the study further highlights the potential of an endocardial-only approach using Adagios purpose-built ventricular ablation technology."
• "These pivotal results represent a noteworthy milestone for Adagio and validate the potential for our ULTA technology to address a significant unmet need for treating one of the most complex and challenging arrhythmias."
• "We believe ULTA has the potential to become a foundational ablation technology for treating the ventricle and we look forward to serving the large, underserved population of patients suffering from VT."
• "The FULCRUM-VT results are a significant clinical achievement and compare favorably against published RF (radiofrequency) benchmarks and the emerging PFA (pulsed field ablation) data for VT."
• "It is the only pivotal IDE trial to show consistent endocardial-only outcomes across both ischemic and non-ischemic cardiomyopathy."

Industry Context

StockSavvy.ai notes that Adagio Medical's positive results for its vCLAS Ventricular Ablation System in the FULCRUM-VT trial position it to compete in the growing market for cardiac ablation technologies, particularly for ventricular tachycardia, an area with significant unmet needs. The reported equivalent effectiveness across different cardiomyopathy types and the endocardial-only approach are key differentiators.

Comparison to Industry Standards

• The results compare favorably against published Radiofrequency (RF) benchmarks for VT ablation.
• The results are also presented in comparison to emerging Pulsed Field Ablation (PFA) data for VT.
• The study achieved equivalent outcomes for both ischemic (ICM) and non-ischemic cardiomyopathy (NICM) patients, which is noted as a first for ablation technology from an endocardial approach and addresses a historically challenging patient cohort.

Stakeholder Impact

• Shareholders: Positive trial results may lead to increased investor confidence and potential stock price appreciation upon FDA approval.
• Patients: Potential for improved treatment outcomes, reduced shocks, and decreased reliance on antiarrhythmic drugs for VT.
• Physicians: Offers a potentially more streamlined and reproducible approach to VT ablation with a favorable safety profile.
• Healthcare System: Potential for reduced hospital readmissions and associated costs.

Next Steps

• Support the company's application for Food and Drug Administration (FDA) Premarket Approval of the vCLAS Ventricular Ablation System.
• Seek the broadest industry indication for purely endocardial ablation of scar-mediated VT.
• Continue research, development, and regulatory plans, including communications with and submissions to the FDA.

Key Dates

Recommendation

The FULCRUM-VT trial results are exceptionally strong, meeting primary endpoints for safety and efficacy, and demonstrating a significant advancement in VT ablation technology. The equivalent performance across different cardiomyopathy types is a key differentiator. These results position Adagio Medical favorably for FDA approval, which could lead to a substantial market opportunity and significant growth, making it an attractive investment.

Keywords

Ventricular Ablation, vCLAS System, FULCRUM-VT Trial, Cardiac Arrhythmias, Ventricular Tachycardia, Catheter Ablation, FDA PMA, Cardiology